Enzon shareholder DellaCamera seeks to declassify company's board

By Lisa Kerner

Charlotte, N.C., Dec. 14 - Enzon Pharmaceuticals, Inc. shareholder DellaCamera Capital Management submitted a shareholder proposal requesting that the company take action to declassify its board of directors, according to a schedule 13D/A filed on Monday with the Securities and Exchange Commission.

The investor wants the proposal included in Enzon's proxy statement for its 2010 annual meeting under rule 14a-8 of the Securities Exchange Act of 1934, as amended, the filing said.

DellaCamera beneficially owns 3,688,100 shares, or 8.1%, of the Bridgewater, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.